Blood Substitutes

Emulsified Formula Could Facilitate Emergency Use

Published in Blood Weekly, August 23rd, 2001

Sanguine Corporation (SGNC) announced that, eight weeks into the emulsification stability study of its synthetic red blood cell substitute PHER-O2, all results to date have been positive.

The study will continue for four more weeks, at which time final results will be analyzed and announced.

"PHER-O2's predecessor, Fluosol, which is the only oxygen-carrying synthetic red blood cell substitute to have received U.S. Food and Drug Administration (FDA) approval, required freezing to ensure stability," Thomas C. Drees, PhD, Sanguine Corporation, stated. "PHER-O2's emulsification formulation, currently being tested for stability, does not require...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry